Nascent Biotech（NBIO）株式概要臨床段階のバイオ医薬品会社であるナセント・バイオテック社は、様々な癌の治療のためのモノクローナル抗体を開発している。 詳細NBIO ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析意味のある時価総額がありません ( $52K )最新の財務報告は1年以上前のものである 株式の流動性は非常に低い すべてのリスクチェックを見るNBIO Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.0077該当なし内在価値ディスカウントEst. Revenue$PastFuture-4m2m2016201920222025202620282031Revenue US$1.0Earnings US$0.2AdvancedSet Fair ValueView all narrativesNascent Biotech, Inc. 競合他社AditxtSymbol: NasdaqCM:ADTXMarket cap: US$40.9kVincerx PharmaSymbol: OTCPK:VINCMarket cap: US$66.5kSynairgenSymbol: OTCPK:SYGG.FMarket cap: US$110.3kLipella PharmaceuticalsSymbol: OTCPK:LIPOMarket cap: US$646.5k価格と性能株価の高値、安値、推移の概要Nascent Biotech過去の株価現在の株価US$0.007752週高値US$0.1352週安値US$0.000001ベータ01ヶ月の変化2,466.67%3ヶ月変化2,466.67%1年変化7,600.00%3年間の変化-85.16%5年間の変化-87.85%IPOからの変化-99.24%最新ニュースお知らせ • Apr 02Nascent Biotech, Inc. Files Form 15Nascent Biotech, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended.お知らせ • Nov 16Nascent Biotech, Inc. announced delayed 10-Q filingOn 11/15/2024, Nascent Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 17Nascent Biotech, Inc. Prepares for Pivotal Phase II Research with Fresh Manufacturing RunNascent Biotech, Inc. announced that it is embarking on a fresh manufacturing run to ensure Pritumumab ("PTB") supplies are at maximum potency when patient dosing begins in the upcoming Phase II clinical trial. This announcement comes as the Company prepares for a Phase II trial that follows a very successful Phase I trial-where safety at five ascending dose cohorts was observed-involving 15 patients who received PTB for various types of brain tumors. The most common and most challenging to treat tumor type in the trial was Gllioblastoma. 12 of 15 patients had this diagnosis. There were no dose-related toxicities. Overall, the study found that single agent Pritumumab is safe up to a dose of 16.2 mg/kg every 7 days in brain tumor patients. One partial response showed a 98.0% and 40.8% reduction in 2 tumor lesions for 21 months on study. Management anticipates that some research sites will open for the start of Phase II testing late this summer with actual patients involved later in 2024.お知らせ • Mar 15Nascent Biotech, Inc. has filed a Follow-on Equity Offering in the amount of $2.4 million.Nascent Biotech, Inc. has filed a Follow-on Equity Offering in the amount of $2.4 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 20,000,000 Price\Range: $0.12 Discount Per Security: $0お知らせ • Aug 23Nascent Biotech to Begin Phase II Clinical Trials for Brain CancerNascent Biotech, Inc. announced that the Company has been cleared by the FDA to begin Phase II clinical trials for brain cancer. This milestone allows the Company to continue advancing Pritumumab through the regulatory clinical processes in its use against Brain Tumors including Glioblastoma. Nascent Biotech therapeutic antibody Pritumumab (PTB) is a natural human antibody originally isolated from lymph nodes of a patient with cervical cancer. This monoclonal antibody targets cell surface Vimentin (also referred to as ectodomain vimentin), shown to be expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy that binds to the tumor and recruits the immune system to eliminate cancer cells.お知らせ • Jan 26Nascent Biotech, Inc. Completes Dosing Requirement in Final Cohort of Phase I Clinical TrialNascent Biotech, Inc. announced the completion of the dosing period of their Phase I Clinical Trial evaluating the safety and dose tolerance of Pritumumab ("PTB") as a treatment for Brain Cancer. The completion of dosing for the fifth and final Phase I cohort completes safety and dose escalation. The Company will now prepare to submit data and the Phase II Clinical Protocol to the United States Food and Drug Administration (the "FDA") for evaluation. As the trial remains open for all active and follow-up participants enrolled, we look forward to providing more data on the safety and tolerability of Pritumumab. PTB is a natural human antibody that binds to Cell surface Vimentin (also referred to as ectodomain vimentin), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy which seeks out only cancer cells while sparing healthy cells.最新情報をもっと見るRecent updatesお知らせ • Apr 02Nascent Biotech, Inc. Files Form 15Nascent Biotech, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended.お知らせ • Nov 16Nascent Biotech, Inc. announced delayed 10-Q filingOn 11/15/2024, Nascent Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 17Nascent Biotech, Inc. Prepares for Pivotal Phase II Research with Fresh Manufacturing RunNascent Biotech, Inc. announced that it is embarking on a fresh manufacturing run to ensure Pritumumab ("PTB") supplies are at maximum potency when patient dosing begins in the upcoming Phase II clinical trial. This announcement comes as the Company prepares for a Phase II trial that follows a very successful Phase I trial-where safety at five ascending dose cohorts was observed-involving 15 patients who received PTB for various types of brain tumors. The most common and most challenging to treat tumor type in the trial was Gllioblastoma. 12 of 15 patients had this diagnosis. There were no dose-related toxicities. Overall, the study found that single agent Pritumumab is safe up to a dose of 16.2 mg/kg every 7 days in brain tumor patients. One partial response showed a 98.0% and 40.8% reduction in 2 tumor lesions for 21 months on study. Management anticipates that some research sites will open for the start of Phase II testing late this summer with actual patients involved later in 2024.お知らせ • Mar 15Nascent Biotech, Inc. has filed a Follow-on Equity Offering in the amount of $2.4 million.Nascent Biotech, Inc. has filed a Follow-on Equity Offering in the amount of $2.4 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 20,000,000 Price\Range: $0.12 Discount Per Security: $0お知らせ • Aug 23Nascent Biotech to Begin Phase II Clinical Trials for Brain CancerNascent Biotech, Inc. announced that the Company has been cleared by the FDA to begin Phase II clinical trials for brain cancer. This milestone allows the Company to continue advancing Pritumumab through the regulatory clinical processes in its use against Brain Tumors including Glioblastoma. Nascent Biotech therapeutic antibody Pritumumab (PTB) is a natural human antibody originally isolated from lymph nodes of a patient with cervical cancer. This monoclonal antibody targets cell surface Vimentin (also referred to as ectodomain vimentin), shown to be expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy that binds to the tumor and recruits the immune system to eliminate cancer cells.お知らせ • Jan 26Nascent Biotech, Inc. Completes Dosing Requirement in Final Cohort of Phase I Clinical TrialNascent Biotech, Inc. announced the completion of the dosing period of their Phase I Clinical Trial evaluating the safety and dose tolerance of Pritumumab ("PTB") as a treatment for Brain Cancer. The completion of dosing for the fifth and final Phase I cohort completes safety and dose escalation. The Company will now prepare to submit data and the Phase II Clinical Protocol to the United States Food and Drug Administration (the "FDA") for evaluation. As the trial remains open for all active and follow-up participants enrolled, we look forward to providing more data on the safety and tolerability of Pritumumab. PTB is a natural human antibody that binds to Cell surface Vimentin (also referred to as ectodomain vimentin), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy which seeks out only cancer cells while sparing healthy cells.お知らせ • Jan 11Nascent Biotech, Inc. Enrolls Final Patient Cohort in Phase I Brain Cancer TrialNascent Biotech, Inc. announced the completion and closure of enrollment for the final cohort of patients involved in the Company's Phase I trial to evaluate Pritumumab ("PTB") as a treatment for Brain Cancer. Following the completion of patient dosing in this fifth and final cohort, the Company's Phase I trial will be complete. The Company will then prepare and submit research data to the FDA in preparation for the launch of its Phase 2 clinical research. PTB is a natural human antibody that binds to Cell surface Vimentin (also referred to as ectodomain vimentin), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy which seeks out only cancer cells while sparing healthy cells.お知らせ • Dec 21Nascent Biotech Announces Appointment of Dr. Ivan Babic to Scientific Advisory BoardNascent Biotech, Inc. announced that Dr. Ivan Babic, a renowned cancer expert, has been appointed to the Company's scientific advisory board. Dr. Babic is currently the Director of Gilman Biosciences. With more than 14 years' experience in translational oncology, he has been actively involved in drug discovery and development for the last 8 years. Dr. Babic has held positions at UCLA and UCSD's Moores Cancer Center. He was also Assistant Professor at the John Wayne Cancer Institute where his lab focused on identifying novel therapeutics for glioblastoma.お知らせ • Oct 06Nascent Biotech, Inc. Begins Enrollment of Final Patient Cohort to Complete Phase One Clinical ResearchNascent Biotech, Inc. announced that the Company has enrolled the first patient of the fifth and final cohort of its Phase I clinical trial to evaluate Pritumumab (PTB) as a treatment for Primary and Metastatic Brain Cancers. Patient enrollment continues for Phase I and interested parties may review trial requirements at www.clinicaltrials.gov under the search term Pritumumab. Following completion of dosing of the Fifth Cohort, the Company will prepare data for submission to the FDA in preparation for Phase II clinical research. PTB is a natural human antibody that binds to Cell surface Vimentin (also referred to as ectodomain vimentin), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy and seek out only cancer cells without damaging healthy cells.お知らせ • Sep 14Nascent Biotech, Inc. Completes Fourth Cohort in Phase 1 Human Trial for Primary and Metastatic Brain CancerNascent Biotech, Inc. announced the completion of the Fourth Cohort in dosing patients in the Company's Phase I trial to evaluate Pritumumab ("PTB") as a treatment for Brain Cancer, including Primary and metastatic Brain Tumors. After reviewing data gathered from the four completed cohorts, this milestone will allow the trial to advance to a fifth and final cohort. Patient enrollment continues for Phase I. Following completion of dosing of the Fifth Cohort, the Phase I trial will be complete, and the Company will prepare data for submission to the FDA in preparation for Phase 2 clinical research.お知らせ • Jun 30Nascent Biotech, Inc. announced delayed annual 10-K filingOn 06/29/2021, Nascent Biotech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Sep 24Brandon Price Resigns as Executive Vice President and Director of Nascent Biotech, Inc, Effective September 30, 2020On September 18, 2020, Brandon Price resigned as Executive Vice President and director of Nascent Biotech Inc. submitted his resignation. Mr. Price resigned for personal reasons due to life priorities and use of time. The company has agreed to accept his resignation effective as of September 30, 2020.お知らせ • Aug 25Nascent Biotech, Inc. announced that it has received $0.74 million in fundingNascent Biotech, Inc. (OTCPK:NBIO) announced that it has received $740,000 in equity funding on August 24, 2020. The transaction included participation from individual investors.株主還元NBIOUS BiotechsUS 市場7D2,466.7%-1.6%-0.8%1Y7,600.0%34.4%27.1%株主還元を見る業界別リターン: NBIO過去 1 年間で34.4 % の収益を上げたUS Biotechs業界を上回りました。リターン対市場: NBIO過去 1 年間で27.1 % の収益を上げたUS市場を上回りました。価格変動Is NBIO's price volatile compared to industry and market?NBIO volatilityNBIO Average Weekly Movementn/aBiotechs Industry Average Movement11.0%Market Average Movement7.2%10% most volatile stocks in US Market16.3%10% least volatile stocks in US Market3.2%安定した株価: NBIOの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のNBIOのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/an/aSean Carrickwww.nascentbiotech.com臨床段階のバイオ医薬品会社であるナスセント・バイオテック社は、様々な癌の治療のためのモノクローナル抗体を開発している。同社は、膠芽腫や悪性星細胞腫などの脳腫瘍や、肺がん、乳がん、大腸がん、脳腫瘍、膵臓がんなどの上皮性がんの患者を治療する薬剤であるプリツムマブを開発している。同社は、がん治療、糖尿病、自己免疫、移植のための独自の技術プラットフォームであるMultiPharmを開発している。また、CLNH5の開発も行っている。ナセント・バイオテック社はフロリダ州ノースパームビーチに本社を置いている。もっと見るNascent Biotech, Inc. 基礎のまとめNascent Biotech の収益と売上を時価総額と比較するとどうか。NBIO 基礎統計学時価総額US$51.85k収益（TTM）-US$1.92m売上高(TTM)n/a0.0xP/Sレシオ0.0xPER（株価収益率NBIO は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計NBIO 損益計算書（TTM）収益US$0売上原価US$297.63k売上総利益-US$297.63kその他の費用US$1.63m収益-US$1.92m直近の収益報告Jun 30, 2024次回決算日該当なし一株当たり利益（EPS）0グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0.0%NBIO の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 20:24終値2026/05/21 00:00収益2024/06/30年間収益2024/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Nascent Biotech, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 02Nascent Biotech, Inc. Files Form 15Nascent Biotech, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended.
お知らせ • Nov 16Nascent Biotech, Inc. announced delayed 10-Q filingOn 11/15/2024, Nascent Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 17Nascent Biotech, Inc. Prepares for Pivotal Phase II Research with Fresh Manufacturing RunNascent Biotech, Inc. announced that it is embarking on a fresh manufacturing run to ensure Pritumumab ("PTB") supplies are at maximum potency when patient dosing begins in the upcoming Phase II clinical trial. This announcement comes as the Company prepares for a Phase II trial that follows a very successful Phase I trial-where safety at five ascending dose cohorts was observed-involving 15 patients who received PTB for various types of brain tumors. The most common and most challenging to treat tumor type in the trial was Gllioblastoma. 12 of 15 patients had this diagnosis. There were no dose-related toxicities. Overall, the study found that single agent Pritumumab is safe up to a dose of 16.2 mg/kg every 7 days in brain tumor patients. One partial response showed a 98.0% and 40.8% reduction in 2 tumor lesions for 21 months on study. Management anticipates that some research sites will open for the start of Phase II testing late this summer with actual patients involved later in 2024.
お知らせ • Mar 15Nascent Biotech, Inc. has filed a Follow-on Equity Offering in the amount of $2.4 million.Nascent Biotech, Inc. has filed a Follow-on Equity Offering in the amount of $2.4 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 20,000,000 Price\Range: $0.12 Discount Per Security: $0
お知らせ • Aug 23Nascent Biotech to Begin Phase II Clinical Trials for Brain CancerNascent Biotech, Inc. announced that the Company has been cleared by the FDA to begin Phase II clinical trials for brain cancer. This milestone allows the Company to continue advancing Pritumumab through the regulatory clinical processes in its use against Brain Tumors including Glioblastoma. Nascent Biotech therapeutic antibody Pritumumab (PTB) is a natural human antibody originally isolated from lymph nodes of a patient with cervical cancer. This monoclonal antibody targets cell surface Vimentin (also referred to as ectodomain vimentin), shown to be expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy that binds to the tumor and recruits the immune system to eliminate cancer cells.
お知らせ • Jan 26Nascent Biotech, Inc. Completes Dosing Requirement in Final Cohort of Phase I Clinical TrialNascent Biotech, Inc. announced the completion of the dosing period of their Phase I Clinical Trial evaluating the safety and dose tolerance of Pritumumab ("PTB") as a treatment for Brain Cancer. The completion of dosing for the fifth and final Phase I cohort completes safety and dose escalation. The Company will now prepare to submit data and the Phase II Clinical Protocol to the United States Food and Drug Administration (the "FDA") for evaluation. As the trial remains open for all active and follow-up participants enrolled, we look forward to providing more data on the safety and tolerability of Pritumumab. PTB is a natural human antibody that binds to Cell surface Vimentin (also referred to as ectodomain vimentin), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy which seeks out only cancer cells while sparing healthy cells.
お知らせ • Apr 02Nascent Biotech, Inc. Files Form 15Nascent Biotech, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended.
お知らせ • Nov 16Nascent Biotech, Inc. announced delayed 10-Q filingOn 11/15/2024, Nascent Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 17Nascent Biotech, Inc. Prepares for Pivotal Phase II Research with Fresh Manufacturing RunNascent Biotech, Inc. announced that it is embarking on a fresh manufacturing run to ensure Pritumumab ("PTB") supplies are at maximum potency when patient dosing begins in the upcoming Phase II clinical trial. This announcement comes as the Company prepares for a Phase II trial that follows a very successful Phase I trial-where safety at five ascending dose cohorts was observed-involving 15 patients who received PTB for various types of brain tumors. The most common and most challenging to treat tumor type in the trial was Gllioblastoma. 12 of 15 patients had this diagnosis. There were no dose-related toxicities. Overall, the study found that single agent Pritumumab is safe up to a dose of 16.2 mg/kg every 7 days in brain tumor patients. One partial response showed a 98.0% and 40.8% reduction in 2 tumor lesions for 21 months on study. Management anticipates that some research sites will open for the start of Phase II testing late this summer with actual patients involved later in 2024.
お知らせ • Mar 15Nascent Biotech, Inc. has filed a Follow-on Equity Offering in the amount of $2.4 million.Nascent Biotech, Inc. has filed a Follow-on Equity Offering in the amount of $2.4 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 20,000,000 Price\Range: $0.12 Discount Per Security: $0
お知らせ • Aug 23Nascent Biotech to Begin Phase II Clinical Trials for Brain CancerNascent Biotech, Inc. announced that the Company has been cleared by the FDA to begin Phase II clinical trials for brain cancer. This milestone allows the Company to continue advancing Pritumumab through the regulatory clinical processes in its use against Brain Tumors including Glioblastoma. Nascent Biotech therapeutic antibody Pritumumab (PTB) is a natural human antibody originally isolated from lymph nodes of a patient with cervical cancer. This monoclonal antibody targets cell surface Vimentin (also referred to as ectodomain vimentin), shown to be expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy that binds to the tumor and recruits the immune system to eliminate cancer cells.
お知らせ • Jan 26Nascent Biotech, Inc. Completes Dosing Requirement in Final Cohort of Phase I Clinical TrialNascent Biotech, Inc. announced the completion of the dosing period of their Phase I Clinical Trial evaluating the safety and dose tolerance of Pritumumab ("PTB") as a treatment for Brain Cancer. The completion of dosing for the fifth and final Phase I cohort completes safety and dose escalation. The Company will now prepare to submit data and the Phase II Clinical Protocol to the United States Food and Drug Administration (the "FDA") for evaluation. As the trial remains open for all active and follow-up participants enrolled, we look forward to providing more data on the safety and tolerability of Pritumumab. PTB is a natural human antibody that binds to Cell surface Vimentin (also referred to as ectodomain vimentin), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy which seeks out only cancer cells while sparing healthy cells.
お知らせ • Jan 11Nascent Biotech, Inc. Enrolls Final Patient Cohort in Phase I Brain Cancer TrialNascent Biotech, Inc. announced the completion and closure of enrollment for the final cohort of patients involved in the Company's Phase I trial to evaluate Pritumumab ("PTB") as a treatment for Brain Cancer. Following the completion of patient dosing in this fifth and final cohort, the Company's Phase I trial will be complete. The Company will then prepare and submit research data to the FDA in preparation for the launch of its Phase 2 clinical research. PTB is a natural human antibody that binds to Cell surface Vimentin (also referred to as ectodomain vimentin), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy which seeks out only cancer cells while sparing healthy cells.
お知らせ • Dec 21Nascent Biotech Announces Appointment of Dr. Ivan Babic to Scientific Advisory BoardNascent Biotech, Inc. announced that Dr. Ivan Babic, a renowned cancer expert, has been appointed to the Company's scientific advisory board. Dr. Babic is currently the Director of Gilman Biosciences. With more than 14 years' experience in translational oncology, he has been actively involved in drug discovery and development for the last 8 years. Dr. Babic has held positions at UCLA and UCSD's Moores Cancer Center. He was also Assistant Professor at the John Wayne Cancer Institute where his lab focused on identifying novel therapeutics for glioblastoma.
お知らせ • Oct 06Nascent Biotech, Inc. Begins Enrollment of Final Patient Cohort to Complete Phase One Clinical ResearchNascent Biotech, Inc. announced that the Company has enrolled the first patient of the fifth and final cohort of its Phase I clinical trial to evaluate Pritumumab (PTB) as a treatment for Primary and Metastatic Brain Cancers. Patient enrollment continues for Phase I and interested parties may review trial requirements at www.clinicaltrials.gov under the search term Pritumumab. Following completion of dosing of the Fifth Cohort, the Company will prepare data for submission to the FDA in preparation for Phase II clinical research. PTB is a natural human antibody that binds to Cell surface Vimentin (also referred to as ectodomain vimentin), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy and seek out only cancer cells without damaging healthy cells.
お知らせ • Sep 14Nascent Biotech, Inc. Completes Fourth Cohort in Phase 1 Human Trial for Primary and Metastatic Brain CancerNascent Biotech, Inc. announced the completion of the Fourth Cohort in dosing patients in the Company's Phase I trial to evaluate Pritumumab ("PTB") as a treatment for Brain Cancer, including Primary and metastatic Brain Tumors. After reviewing data gathered from the four completed cohorts, this milestone will allow the trial to advance to a fifth and final cohort. Patient enrollment continues for Phase I. Following completion of dosing of the Fifth Cohort, the Phase I trial will be complete, and the Company will prepare data for submission to the FDA in preparation for Phase 2 clinical research.
お知らせ • Jun 30Nascent Biotech, Inc. announced delayed annual 10-K filingOn 06/29/2021, Nascent Biotech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Sep 24Brandon Price Resigns as Executive Vice President and Director of Nascent Biotech, Inc, Effective September 30, 2020On September 18, 2020, Brandon Price resigned as Executive Vice President and director of Nascent Biotech Inc. submitted his resignation. Mr. Price resigned for personal reasons due to life priorities and use of time. The company has agreed to accept his resignation effective as of September 30, 2020.
お知らせ • Aug 25Nascent Biotech, Inc. announced that it has received $0.74 million in fundingNascent Biotech, Inc. (OTCPK:NBIO) announced that it has received $740,000 in equity funding on August 24, 2020. The transaction included participation from individual investors.
